(Circulation. 1997;96:2197-2205.)
© 1997 American Heart Association, Inc.
Articles |
Prognostic Value of Bisoprolol-Induced Hemodynamic Effects in Heart Failure During the Cardiac Insufficiency BIsoprolol Study (CIBIS)
From the Service de pharmacologie and Institut Fédératif de Recherche en Physiopathologie et Génétique Cardiovasculaire, Hôpital Pitié Salpétrière (P.L.), Paris, France; Unité INSERM U 436, Service d'informatique médicale, CHU Pitié Salpétrière (S.E., J.L.G., A.M.), Paris, France; Service de cardiologie, Hôpital de Corbeil (H.L.), Corbeil Essonne, France; Service de cardiologie, Hôpital Kremlin Bicètre (S.W.), Le Kremlin Bicètre, France; Medisch Centrum Alkmaar (J.A.H.), Almaar, Holland; Department Internal Medicine Cardiology, Philips University (B.M.), Marburg, Germany; Zentrum für Innere Medizin (M.H.), Universitätsklinikum, Obere Eselberg, Ulm, Germany; Unité de pharmacologie clinique, Hôpital Saint Antoine (P.J.), Paris, France; and Unité de pharmacologie clinique, Hôpitaux de Lyon (J.-P.B.), Lyon, France.
Correspondence to Philippe Lechat, Service de pharmacologie, Hôpital Pitié Salpétrière, 47 Boulevard de l'Hôpital, 75013 Paris, France. E-mail philippe.lechat{at}psl.ap-hop-paris.fr
Background To further evaluate the mechanism of ß-blocker–induced benefits in heart failure, the relationships between bisoprolol-induced hemodynamic effects and survival were studied during the Cardiac Insufficiency BIsoprolol Study (CIBIS).
Methods and Results In 557 patients studied, bisoprolol significantly reduced heart rate (-16.3±15.3 versus -1.6±13.4 bpm, respectively; P<.001) compared with placebo at 2 months after inclusion in the study. Heart rate change over time had the highest predictive value for survival (P<.01). Left ventricular fractional shortening (LVFS) significantly increased in the bisoprolol group compared with the placebo group 5 months after inclusion (+0.04±0.06 versus -0.001±0.05, respectively; P<.001; n=160). LVFS change over time was also significantly correlated with further survival (P<.02 by Cox analysis). Using a nonparametric approach, we demonstrated a significant interaction between study treatment group and LVFS over time. Patients who demonstrated improvement of LVFS over time (82% and 51% of patients in the bisoprolol and the placebo groups, respectively; P<.02) were at lower risk, but the hazard did not further decrease with a further increase of fractional shortening, and there was no significant difference between study treatment groups. Finally, it could be demonstrated that each of the three factors (heart rate change over time, LVFS change over time, and bisoprolol treatment) made a specific contribution to mortality rate.
Conclusions Preservation of left ventricular function appears to play a key role in the bisoprolol-induced beneficial effects on prognosis in heart failure. Short-term ß-blocker–induced cardiac effects could provide a means to identify those patients who will experience improved survival over the long term.
Key Words: heart failure • survival • bisoprolol
This article has been cited by other articles:
 |
|
 |
|
  D. Chen, R. Chang, B. Umakanthan, L. N. Stoletniy, and J. T. Heywood Improvement of Cardiac Function Persists Long Term With Medical Therapy for Left Ventricular Systolic Dysfunction Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 220 - 226. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al. Resting Heart Rate in Cardiovascular Disease J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghio, G. Magrini, A. Serio, C. Klersy, A. Fucilli, A. Ronaszeki, P. Karpati, G. Mordenti, A. Capriati, P. A. Poole-Wilson, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy Eur. Heart J., March 1, 2006; 27(5): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Metra, C. Torp-Pedersen, K. Swedberg, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, B. Lutiger, A. Scherhag, M. A. Lukas, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial Eur. Heart J., November 1, 2005; 26(21): 2259 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T A M Kaandorp, H J Lamb, J J Bax, E Boersma, E P Viergever, E E van der Wall, and A de Roos Prediction of beneficial effect of {beta} blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance Heart, November 1, 2005; 91(11): 1471 - 1472. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cascorbi, M. Paul, and H. K. Kroemer Pharmacogenomics of heart failure - focus on drug disposition and action Cardiovasc Res, October 1, 2004; 64(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jin, G. Fedorowicz, R. Yang, A. Ogasawara, F. Peale, T. Pham, and N. F. Paoni Thyrotropin-Releasing Hormone Is Induced in the Left Ventricle of Rats With Heart Failure and Can Provide Inotropic Support to the Failing Heart Circulation, May 11, 2004; 109(18): 2240 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Eichhorn, P. A. Grayburn, S. A. Mayer, M. St John Sutton, C. Appleton, J. Plehn, J. Oh, B. Greenberg, A. DeMaria, R. Frantz, et al. Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With {beta}-Blockade in Patients With Heart Failure: The {beta}-Blocker Evaluation of Survival Trial (BEST) Circulation, November 11, 2003; 108(19): 2336 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bello, D. J. Shah, G. M. Farah, S. Di Luzio, M. Parker, M. R. Johnson, W. G. Cotts, F. J. Klocke, R. O. Bonow, R. M. Judd, et al. Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing {beta}-Blocker Therapy Circulation, October 21, 2003; 108(16): 1945 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R H Arnold, E Kotlyar, C Hayward, A M Keogh, and P S Macdonald Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study Heart, March 1, 2003; 89(3): 293 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon? J. Nucl. Med., April 1, 2002; 43(4): 536 - 539. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Szili-Torok, G. P. Kimman, D. Theuns, D. Poldermans, J. R. T. C. Roelandt, and L. J. Jordaens Deterioration of left ventricular function following atrio-ventricular node ablation and right ventricular apical pacing in patients with permanent atrial fibrillation Europace, January 1, 2002; 4(1): 61 - 65. [Full Text] [PDF]
|
|
|
|
|
|
L. Jordaens and T. Szili-Torok Between Scylla and Charybdis: a choice between equally dreadful alternatives Europace, January 1, 2002; 4(3): 215 - 218. [PDF]
|
|
|
|
|
|
C. Maack, T. Elter, G. Nickenig, K. LaRosee, M. Crivaro, A. Stablein, H. Wuttke, and M. Bohm Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure J. Am. Coll. Cardiol., October 1, 2001; 38(4): 939 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lechat, J.-S. Hulot, S. Escolano, A. Mallet, A. Leizorovicz, M. Werhlen-Grandjean, G. Pochmalicki, and H. Dargie Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Circulation, March 13, 2001; 103(10): 1428 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Ramahi, M. D. Longo, A. R. Cadariu, K. Rohlfs, S. A. Carolan, K. M. Engle, H. Samady, and F. J. T. Wackers Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy J. Am. Coll. Cardiol., March 1, 2001; 37(3): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Josephson, D. J. Callans, and A. E. Buxton The Role of the Implantable Cardioverter-Defibrillator for Prevention of Sudden Cardiac Death Ann Intern Med, December 5, 2000; 133(11): 901 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Cohn, R. Ferrari, N. Sharpe, and on Behalf of an International Forum on Cardiac Rem Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J. Am. Coll. Cardiol., March 1, 2000; 35(3): 569 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bristow {beta}-Adrenergic Receptor Blockade in Chronic Heart Failure Circulation, February 8, 2000; 101(5): 558 - 569. [Full Text] [PDF]
|
|
|
|
|
|
T Laperche, D Logeart, A Cohen-Solal, and R Gourgon Potential interests of heart rate lowering drugs Heart, April 1, 1999; 81(4): 336 - 341. [Full Text]
|
|
|
|
|
|
D. Grimm, D. Cameron, D. P. Griese, G. A.J. Riegger, and E. P. Kromer Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction Cardiovasc Res, November 1, 1998; 40(2): 297 - 306. [Abstract] [Full Text] [PDF]
|
|